CoChat
Sign Up
Cited by 28

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF

Triviai, Ioanna, Zeschke, Silke, Rentel, Jan, Spanakis, Marios, Scherer, Theo, Gabdoulline, Razif, Panagiota, Victoria, Thol, Felicitas, Heuser, Michael, Stocking, Carol, Kröger, Nicolaus·2019·Leukemia
DOI 10.1038/s41375-018-0159-0
Open this paper in CoChat — free account

Abstract

Primary myelofibrosis (PMF) is a hematopoietic stem cell (HSC) disease, characterized by aberrant differentiation of all myeloid lineages and profound disruption of the bone marrow niche. PMF samples carry several mutations, but their cell origin and hierarchy in regulating the different waves of clonal and aberrant myeloproliferation from the prime HSC compartment is poorly understood. Genotyping of >2000 colonies from CD133+HSC and progenitors from PMF patients confirmed the complex genetic heterogeneity within the neoplastic population. Notably, mutations in chromatin regulators ASXL1 and/or EZH2 were identified as the first genetic lesions, preceding both JAK2-V617F and CALR mutations, and are thus drivers of clonal myelopoiesis in a PMF subset. HSC from PMF patients with double ASXL1/EZH2 mutations exhibited significantly higher engraftment in immunodeficient mice than those from patients without histone modifier mutations. EZH2 mutations correlate with aberrant erythropoiesis in PMF patients, exemplified by impaired maturation and cell cycle arrest of erythroid progenitors. These data underscore the importance of post-transcriptional modifiers of histones in neoplastic stem cells, whose clonal growth sustains aberrant myelopoiesis and expansion of pre-leukemic clones in PMF.

Overview

Integrity signals

Registry

Crossref · 10.1038/s41375-018-0159-0

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 3 references

Research works printed but not linked: 31

  1. Campbell P, Green A. The myeloproliferative disorders. New Engl J Med. 2006;355:2452–66. · DOI
  2. Rumi E, Cazzola M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood. 2017;129:680–92. · DOI
  3. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel J, Brunel J-P, Mermel C, et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood. 2014;123:e123–133. · DOI
  4. Shih A, Abdel-Wahab O, Patel J, Levine R. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12:599–612. · DOI · Paper page
  5. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667–79. · DOI · Paper page
  6. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123:2220–8. · DOI
  7. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. New Engl J Med. 2015;372:601–12. · DOI · Paper page
  8. Triviai I, Stübig T, Niebuhr B, Hussein K, Tsiftsoglou A, Fehse B, et al. CD133 marks a stem cell population that drives human primary myelofibrosis. Haematologica. 2015;100:768–79. · DOI
  9. Thol F, Suchanek K, Koenecke C, Stadler M, Platzbecker U, Thiede C, et al. SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia. 2013;27:2072–5. · DOI
  10. Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, et al. Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia. 2017;31:1286–95. · DOI
  11. Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuk F, Wolschke C, et al. Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:872–3. · DOI
  12. Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood. 2007;109:1316–21. · DOI
  13. Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander A, et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant. 2010;45:1404–7. · DOI
  14. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012;22:180–93. · DOI
  15. Dey A, Seshasayee D, Noubade R, French D, Liu J, Chaurushiya M, et al. Loss of the tumor suppressor BAP1 causes myeloid transformation. Science. 2012;337:1541–6. · DOI
  16. Carbuccia N, Murati A, Trouplin V, Brecqueville M, Adélaïde J, Rey J, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia. 2009;23:2183–6. · DOI
  17. Sorigué M, Ribera J, García O, Cabezón M, Vélez P, Marcé S, et al. Highly variable mutational profile of ASXL1 in myelofibrosis. Eur J Haematol. 2016;97:331–5. · DOI
  18. Guglielmelli P, Pacilli A, Rotunno G, Rumi E, Rosti V, Delaini F, et al. Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood. 2017;129:3227–36. · DOI
  19. Anjos-Afonso F, Currie E, Palmer H, Foster K, Taussig D, Bonnet D. CD34(-) cells at the apex of the human hematopoietic stem cell hierarchy have distinctive cellular and molecular signatures. Cell Stem Cell. 2013;13:161–74. · DOI
  20. Bhatia M, Bonnet D, Murdoch B, Gan O, Dick J. A newly discovered class of human hematopoietic cells with SCID-repopulating activity. Nat Med. 1998;4:1038–45. · DOI
  21. Goodell M, Rosenzweig M, Kim H, Marks D, DeMaria M, Paradis G, et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med. 1997;3:1337–45. · DOI
  22. Ishii M, Matsuoka Y, Sasaki Y, Nakatsuka R, Takahashi M, Nakamoto T, et al. Development of a high-resolution purification method for precise functional characterization of primitive human cord blood-derived CD34-negative SCID-repopulating cells. Exp Hematol. 2011;39:203–13. · DOI
  23. Manz M, Milyamoto T, Akashi K, Weissmann I. Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci USA. 2002;99:11872–7. · DOI
  24. Nangalia J, Nice FL, Wedge DC, Godfrey AL, Grinfeld J, Thakker C, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015;100:42. · DOI
  25. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126:9–16. · DOI · Paper page
  26. Zink F, Stacey SN, Norddahl GL, Frigge ML, Magnusson OT, Jonsdottir I, et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017;130:742–52. · DOI · Paper page
  27. Busque L, Patel J, Figueroa M, Vasanthakumar A, Provost S, Hamilou Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012;44:1179–81. · DOI · Paper page
  28. Sashida G, Wang C, Tomioka T, Oshima M, Aoyama K, Kanai A, et al. The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med. 2016;213:1459–77. · DOI
  29. Shi H, Yamamoto S, Sheng M, Bai J, Zhang P, Chen R, et al. ASXL1 plays an important role in erythropoiesis. Sci Rep. 2016;6:28789. · DOI
  30. Shimizu T, Kubovcakova L, Nienhold R, Zmajkovic J, Meyer SC, Hao-Shen H, et al. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. J Exp Med. 2016;213:1479–96. · DOI
  31. Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127:3410–23. · DOI

Cited by

See all 28

Metadata

Authors
Triviai, I., Zeschke, S., Rentel, J., Spanakis, M., Scherer, T., Gabdoulline, R., Panagiota, V., Thol, F., Heuser, M., Stocking, C., & Kröger, N.
Venue
Leukemia
Publisher
Springer Science and Business Media LLC
Published
2018-06-15
Volume
33
Issue
1
Pages
99-109
ISSN
  • 0887-6924
  • 1476-5551
DOI
10.1038/s41375-018-0159-0
Cited by
28
References
3
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. https://app.cochat.ai/papers/10.1038/s41375-018-0159-0
The paper
Triviai, I., Zeschke, S., Rentel, J., Spanakis, M., Scherer, T., Gabdoulline, R., Panagiota, V., Thol, F., Heuser, M., Stocking, C., & Kröger, N. (2019). ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Leukemia. https://doi.org/10.1038/s41375-018-0159-0